Fundraising FoxVivo Capital — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)Rahul Kakkar(Director)inGreg Bell(Executive Officer)
Co-investorsAlpha Wave GlobalBioBritLifeSci Venture PartnersvenBio PartnersJanus Henderson InvestorsREDMILE+2 more
Clasp Therapeutics develops off-the-shelf precision T cell engagers (its proprietary pHLАre molecules) that target mutant peptide-HLA complexes displayed on cancer cells, directing T cells to destroy tumors carrying common driver mutations such as KRas.
BiotechHealthtechCambridge, US
Co-investorsCatalio Capital Management, LPCure VenturesBrightEdgeCatalio Capital ManagementNovo HoldingsThird Rock Ventures
Regulus is a Japanese company working on recruiting automation software.
Future of WorkHR Tech
Max Koenig
Co-investors500 GlobalSierra VenturesCanaan Partners IsraelF2 Venture CapitalNew Enterprise Associates (NEA)RA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.